Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe

OBJECTIVES: The efficacy and safety of certolizumab pegol (CZP), an Fc-free, PEGylated anti-TNF, in axial spondyloarthritis (axSpA) has been established in clinical trial settings. We report CZP effectiveness and safety in European clinical practice in patients with axSpA, including radiographic (r-...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Rheumatology (Oxford)
Главные авторы: Baraliakos, Xenofon, Witte, Torsten, De Clerck, Luc, Frediani, Bruno, Collantes-Estévez, Eduardo, Katsifis, Gkikas, VanLunen, Brenda, Kleine, Elisabeth, Hoepken, Bengt, Bauer, Lars, Goodson, Nicola
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2020
Предметы:
Clinical Science
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7785316/
https://ncbi.nlm.nih.gov/pubmed/32584415
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/keaa181
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы